1
Toufike Kanouni
Qing Dong, Toufike Kanouni, Michael B Wallace: MAPK/ERK kinase inhibitors. Takeda Pharmaceutical Company, David M Stemerick, Mitchell R Brustein, September 20, 2011: US08022057 (1 worldwide citation)

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


2
Toufike Kanouni
MarK Adams, Qing Dong, Toufike Kanouni, Stephen W Kaldor, Nicholas Scorah, Michael B Wallace: Mapk/erk kinase inhibitors. Takeda Pharmaceutical Company, Takeda San Diego, May 14, 2009: US20090124595-A1

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


3
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas DP Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt Activity. Merck And Co, November 20, 2008: US20080287457-A1

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


4
Wei Chen, David J Loury, Tarak D Mody: Pyrazolo-pyrimidine inhibitors of Brutons tyrosine kinase. Pharmacyclics, Wilson Sonsini Goodrich & Rosati, June 22, 2010: US07741330 (85 worldwide citation)

Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.


5
Wei Chen, David J Loury, Tarak D Mody: Pyrazolo-pyrimidine inhibitors of brutons tyrosine kinase. Pharmacyclics, Wilson Sonsini Goodrich & Rosati, May 18, 2010: US07718662 (84 worldwide citation)

Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.


6
Dack Kevin Neil, Whitlock Gavin Alistair: Metalloprotease inhibitors. Pfizer, Pfizer, July 28, 1999: EP0931788-A2 (76 worldwide citation)

Compounds of formula (I): where the substituents are as defined herein, and salts thereof, are matrix metalloprotease inhibitors.


7
Nakahira Hiroyuki: Xanthine derivative. Sumitomo Pharmaceut, October 21, 2003: JP2003-300977 (73 worldwide citation)

PROBLEM TO BE SOLVED: To obtain a compound with high DPP-IV inhibitory activity or improved safety, toxicity, etc.SOLUTION: The xanthine derivative is represented by formula [ring E is a six-membered or seven-membered hydrocarbon ring or a six-membered or seven-membered hetero ring or the like; R1 a ...


8
Schimmel Paul, Wakasugi Keisuke: Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis. Scripps Research Inst, January 15, 2003: EP1274834-A1 (63 worldwide citation)

Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.


9
Shokat Kevan M, Knight Zachary A, Apsel Beth: Kinase antagonists. The Regents Of The University Of California, Shokat Kevan M, Knight Zachary A, Apsel Beth, JENKINS Kenneth E, October 11, 2007: WO/2007/114926 (61 worldwide citation)

The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PDKinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.


10
Ji Qun Sheng, Arnold Lee D, Mulvihill Mark Joseph: Combination of igfr inhibitor and anti-cancer agent. Osi Pharmaceuticals, Ji Qun Sheng, Arnold Lee D, Mulvihill Mark Joseph, BLAKEY Alison, July 5, 2007: WO/2007/075554 (54 worldwide citation)

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGFlR inhibitor compound of Formula I combination, with or withou ...